4.6 Article

Augmentation of cutaneous immune responses by ATPγS:: Purinergic agonists define a novel class of immunologic adjuvants

Journal

JOURNAL OF IMMUNOLOGY
Volume 174, Issue 12, Pages 7725-7731

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.174.12.7725

Keywords

-

Categories

Funding

  1. NIAID NIH HHS [AI59226] Funding Source: Medline

Ask authors/readers for more resources

Extracellular nucleotides activate ligand-gated P2XR ion channels and G protein-coupled P2YRs. In this study we report that intradermal administration of ATP gamma S, a hydrolysis-resistant P2 agonist, results in an enhanced contact hypersensitivity response in mice. Furthermore, ATP gamma S enhanced the induction of delayed-type hypersensitivity to a model tumor vaccine in mice and enhanced the Ag-presenting function of Langerhans cells (LCs) in vitro. Exposure of a LC-like cell line to ATP gamma S in the presence of LPS and GM-CSF augmented the induction of I-A, CD80, CD86, IL-1 beta, and IL-12 p40 while inhibiting the expression of IL-10, suggesting that the immunostimulatory activities of purinergic agonists in the skin are mediated at least in part by P2Rs on APCs. In this regard, an LC-like cell line was found to express mRNA for P2X(1), P2X(7), P2Y(1), P2Y(2), P2Y(4), P2Y(9), and P2Y(11) receptors. We suggest that ATP, when released after trauma or infection, may act as an endogenous adjuvant to enhance the immune response, and that P2 agonists may augment the efficacy of vaccines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available